Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal protein transmembrane 4 beta (LAPTM4B)
- Target
- LAPTM4B
- Molecular classification
- Transmembrane protein, Lysosomal membrane protein, Tetra-transmembrane domain protein
01
Overview
Lysosomal protein transmembrane 4 beta (LAPTM4B) is an integral lysosomal/tetraspan membrane protein implicated in endosome transport, lysosomal function, and signal transduction pathways. It facilitates amino acid transport into lysosomes, regulates key growth and survival signaling pathways such as mTORC1, and controls membrane protein trafficking and degradation (e.g., EGFR)[1][2][4]. LAPTM4B is overexpressed in several cancers, where it may impact tumor progression, cell proliferation, apoptosis resistance, metastasis, and possibly multidrug resistance, making it a biomarker and potential therapeutic interest in oncology[3][4].\n\nNote:\nThere is no validated gene, protein, or drug target officially named "lysosomal protein transmembrane 4 beta pseudogene 2" or "LAPTM4BP2." Results above are for the bona fide target **Lysosomal protein transmembrane 4 beta (LAPTM4B)**. For structured data, "LAPTM4BP2" should be mapped or corrected to "LAPTM4B" with is_incorrect as true for the input.
- Other names
- LAPTM4B-35LAPTM4B-24lysosome-associated protein transmembrane 4 beta
02
Mechanism of action
Not directly drugged, but implicated in pathways affecting: mTORC1 signaling activation; EGFR degradation and signaling modulation; Lysosomal trafficking and function; Potential mediator of drug resistance in cancer
03
Biological functions
Endosome transport via the multivesicular body sorting pathwayRegulation of lysosomal membrane permeabilityAmino acid transport into the lysosome (regulation of mTORC1 activation)Negative regulation of macromolecule metabolic processesNegative regulation of TGFB1 production in regulatory T cellsCeramide binding and control of cell death pathways
04
Disease associations
Cancer (implicated especially in hepatocellular carcinoma, breast cancer, gallbladder cancer, ovarian cancer, cholangiocarcinoma)Possible involvement in tumor progression, metastasis, and chemoresistance
05
Safety considerations
Not a direct therapeutic target, so safety issues are undefined; however, overexpression/activation may enhance tumor growth or drug resistance
06
Biomarkers
Overexpression of LAPTM4B protein in serum and tissue as a biomarker for several cancers (notably breast and liver cancers)Certain polymorphisms (LAPTM4B*1, LAPTM4B*2 alleles) associated with cancer risk and prognosis
Beyond the preview
Go deeper on Lysosomal protein transmembrane 4 beta (LAPTM4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lysosomal protein transmembrane 4 beta (LAPTM4B).